Dr. Lener is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
353 Lexington Avenue
Room 600
New York, NY 10016Phone+1 240-389-2381Fax+1 240-389-2381
Education & Training
Clinical Center at the National Institutes of HealthFellowship, National Institute of Mental Health, 2015 - 2018
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 2011 - 2015
George Washington University School of Medicine and Health SciencesClass of 2011
University of PennsylvaniaB.A., Biological Basis of Behavior, 1996 - 2000
Certifications & Licensure
MD State Medical License 2015 - 2026
NY State Medical License 2013 - 2025
CO State Medical License 2021 - 2023- American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 273 citationsGlutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to KetamineMarc S. Lener, Mark J. Niciu, Elizabeth D. Ballard, Minkyung Park, Lawrence Park
Biological Psychiatry. 2017-05-15 - 22 citationsA Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression.Lawrence Park, Marc S. Lener, Matthew Hopkins, Nicolas Iadorola, Rodrigo Machado-Vieira
Journal of Clinical Psychopharmacology. 2017-06-01 - 210 citationsKetamine for rapid reduction of suicidal ideation: a randomized controlled trial.James W. Murrough, Laili Soleimani, Kaitlin E. DeWilde, Katherine A. Collins, Kyle A. Lapidus
Psychological Medicine. 2015-12-01
Journal Articles
- Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat DepressionLener MS, Kadriu B, Zarate C, Drugs, 2/14/2017
Authored Content
- F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018
- F173. Negative Trial of Scopolamine in Major Depressive Disorder Does Not Demonstrate Neurophysiological Changes Seen with the Antidepressant Response of KetamineApril 2018
Professional Memberships
- Member
- Society of Biological PsychiatryMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
